uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Show others and affiliations
2013 (English)In: Epilepsy Research, ISSN 0920-1211, E-ISSN 1872-6844, Vol. 105, no 3, 362-367 p.Article in journal (Refereed) Published
Abstract [en]

Diazepam rectal gel (Diastat (R)) is the only FDA-approved product indicated for acute repetitive seizures. Despite its proven efficacy, most older children and adults object to this route of administration. As a result, many patients do not realize the benefit of a therapy that can improve outcomes and decrease healthcare costs. Intranasal administration of benzodiazepines offers a potential alternative. The primary objective of this study was to compare the bioavailability and pharmacokinetics of two novel intranasal (IN) diazepam (DZP) formulations versus intravenous (IV) administration in healthy volunteers. Twenty-four healthy volunteers were randomized into an open-label, three-way crossover study. 10 mg doses of two investigational intranasal DZP formulations (solution, suspension) and a 5 mg IV dose of commercially available DZP injectable, USP were given. A two-week washout period separated treatments. Plasma samples for DZP analysis were collected pre-dose and at regular intervals up to 240 h post-dose. DZP concentration-time data were analyzed using a non-compartmental pharmacokinetics approach. Exposure following administration of DZP IN solution (absolute bioavailability - 97%) was greater than the IN suspension (absolute bioavailability - 67%). Mean C-max values for the suspension and solution formulations were 221 ng/mL and 272 ng/mL, respectively. Median time to maximum concentration (T-max) was 1 h and 1.5 h for suspension and solution formulation, respectively. Both investigational intranasal formulations were well tolerated. The results of this pilot study indicate that development of an intranasal diazepam formulation with high bioavailability, reasonable variability, and good tolerability is feasible.

Place, publisher, year, edition, pages
2013. Vol. 105, no 3, 362-367 p.
Keyword [en]
Acute repetitive seizures, Diazepam, Intranasal therapy, Seizure emergencies, Out-of-hospital
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-206566DOI: 10.1016/j.eplepsyres.2013.02.018ISI: 000322357300012OAI: oai:DiVA.org:uu-206566DiVA: diva2:644905
Available from: 2013-09-02 Created: 2013-09-02 Last updated: 2013-09-02Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ivaturi, Vijay D.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Epilepsy Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 243 hits
ReferencesLink to record
Permanent link

Direct link